2-aminopurine has been researched along with Glioblastoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barazas, M; De Witt Hamer, PC; Geerts, D; Gray, NS; Hagemann, C; Hiddingh, L; Kerami, M; Kessler, AF; Kwiatkowski, N; Lagerweij, T; Lewandrowski, G; Niers, JM; Nilsson, RJ; Noske, DP; Sol, N; Tannous, BA; Van der Stoop, PM; Van Tellingen, O; Vandertop, WP; Wang, J; Wedekind, L; Würdinger, T; Zhou, W | 1 |
1 other study(ies) available for 2-aminopurine and Glioblastoma
Article | Year |
---|---|
Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.
Topics: 2-Aminopurine; Animals; Antimitotic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Survival; Drug Resistance, Neoplasm; France; Frozen Sections; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Netherlands; ortho-Aminobenzoates; Paclitaxel; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; RNA Interference; United States; Up-Regulation; Vincristine; Xenograft Model Antitumor Assays | 2013 |